GlaxoSmithKline PLC has agreed to pay up to $2.2 billion to settle more than 90% of pending U.S. state court product liability cases involving Zantac. These lawsuits claim that a discontinued version of the heartburn medication contained NDMA, a probable human carcinogen, which led to cancer in numerous users.
This settlement marks a significant step in addressing the claims of individuals and families affected by Zantac-related health issues. If you believe Zantac may have impacted your health, now is the time to consult with experienced Zantac lawsuit attorneys to understand your legal options.